Category by items | All publications (N = 529) |
---|---|
No. of authors [median (first to third quartile)] | 6 (4 to 8) |
≤ 4 | 171 (32.33%) |
5 ~ 8 | 278 2.55%) |
> 8 | 80 (15.12%) |
Year of publish | |
2011 | 35 (6.62%) |
2012 | 44 (8.32%) |
2013 | 56 (10.59%) |
2014 | 117 (22.12%) |
2015 | 120 (22.68%) |
2016 | 85 (16.07%) |
2017 (up to July-31) | 72 (13.61%) |
Database searched [median ((first to third quartile))] | 2 (2 to 3) |
≤ 1 | 61 (11.53%) |
2 ~ 3 | 385 (72.78%) |
> 3 | 83 (15.69%) |
Journal distribution (n = 174 for journal numbers) | |
Specialist journal | 410 (77.50%) |
General journal | 119 (22.50%) |
Methodologist involved | |
Yes | 349 (65.97%) |
No | 180 (34.03%) |
Design of source study | |
Cohort | 318 (60.11%) |
Case-control | 7 (1.32%) |
Cross-section | 3 (0.57%) |
Mixed | 199 (37.62%) |
CCT and RCT | 2 (0.38%) |
Classification of subject | |
Epidemiology | 525 (99.24%) |
Intervention | 1 (0.19%) |
Prognosis | 2 (0.38%) |
Diagnose | 1 (0.19%) |
Primary outcome | |
Cancer | 260 (49.15%) |
CVD | 118 (22.31%) |
Type 2 Diabetes | 45 (8.51%) |
Fracture and Osteoarthritis | 21 (3.97%) |
CVD and Cancer/Diabetes | 13 (2.46%) |
Metabolic Syndrome or Obesity | 13 (2.46%) |
Pregnancy Outcomes (e.g. neonatal death, low birth weight) | 12 (2.27%) |
Dementia/Cognitive impairment/Alzheimer’s Disease/Parkinson’s disease | 12 (2.27%) |
Depression | 6 (1.13%) |
Digestive tract disease (e.g. pancreatitis, gallbladder disease) | 12 (2.27%) |
Urinary System disease (e.g. urolithiasis) | 6 (1.13%) |
Others (e.g. Cataract, Gout) | 12 (2.27%) |
No. of included studies [median ((first to third quartile))] | 14 (10 to 21) |
≤ 10 | 151 (28.54%) |
11 ~ 21 | 247 (46.69%) |
> 21 | 130 (24.57%) |
Missing | 1 (0.19%) |
Region | |
Asian | 350 (66.16%) |
European | 129 (24.39%) |
America | 47 (8.88%) |
Australia | 3 (0.57%) |
Reporting checklist | |
PRISMA | 109 (20.60%) |
MOOSE | 204 (38.56%) |
PRISMA + MOOSE | 31 (5.86%) |
Other | 6 (1.13%) |
None | 179 (33.84%) |
Model used in trend approximationa | |
RCS regression | 295 (55.77%) |
FP regression | 61 (11.53%) |
Other non-linear regression | 21 (3.97%) |
Linear | 152 (28.73%) |
Funding | |
Yes | 337 (63.71%) |
No | 54 (10.21%) |
Not reported | 138 (26.09%) |